Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
November 08, 2025 11:45 ET | Source: Vor Biopharma Treatment with telitacicept…
AV-Comparatives Publishes 2025 Endpoint Prevention & Response (EPR) Test – The Most Comprehensive Enterprise Cybersecurity Evaluation to Date
INNSBRUCK, Austria, Sept. 22, 2025 /PRNewswire/ -- AV-Comparatives, the leading independent cybersecurity…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are…
